Safety of Etanercept in Patients at High Risk for Mycobacterial Tuberculosis Infections

被引:25
作者
Aggarwal, Rohit [1 ]
Manadan, Augustine M. [1 ]
Poliyedath, Anupama [2 ]
Sequeira, Winston [1 ,2 ]
Block, Joel A. [1 ]
机构
[1] Rush Univ, Med Ctr, Dept Rheumatol, Chicago, IL 60612 USA
[2] John H Stroger Jr Hosp Cook Cty, Chicago, IL USA
关键词
ETANERCEPT; TUBERCULOSIS; POSITIVE PURIFIED PROTEIN DERIVATIVE; TUMOR NECROSIS FACTOR INHIBITORS; NECROSIS-FACTOR ANTAGONISTS; FOREIGN-BORN PERSONS; UNITED-STATES; RHEUMATOID-ARTHRITIS; REACTIVATION;
D O I
10.3899/jrheum.081041
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. The magnitude of the risk of reactivation Of tuberculosis (TB) on use of etanercept, especially in patients with positive purified protein derivative (PPD) test, has not been assessed. We evaluated the risk of developing active TB among PPD-positive patients treated with etanercept. Methods. All patients with a positive PPD test, as defined by American Thoracic Society guidelines, who received etanercept at Cook County Hospital from 2001 to 2008 were retrospectively reviewed. The primary endpoint was the development of active TB either while receiving or after completing etanercept therapy. Results. Four hundred eighty-seven patients received etanercept, of whom 84 were PPD-positive and constituted the primary cohort. The cohort was composed largely of patients who were at high risk for development of active TB: born in endemic area (80%), ethnic/racial minorities (51 Hispanic, 16 African American. and 8 Asian), and low socioeconomic status (66, 78.57%). Overall etanercept exposure was a mean of 24.6 months (range 3 to 60 mo), with 196 patient-years of etanercept exposure in PPD-positive individuals. Indications for etanercept use included rheumatoid arthritis 58 (69%), ankylosing spondylitis 11 (13%), psoriatic arthritis 13 (15.5%), juvenile inflammatory arthritis 1 (1.2%), and vasculitis 1 (1.2%). Of the 80 subjects. 74 received treatment for latent TB infection (LTBI) prior to initiating etanercept. A comprehensive review of these patients' medical records failed to reveal any active TB infection. Conclusion. This systematic analysis suggests that the risk of reactivation of LTBI during etanercept therapy is low in appropriately treated individuals. (First Release April 1 2009; J Rheumatol 2009;36:914-7; doi:10.3899/jrheum.081041)
引用
收藏
页码:914 / 917
页数:4
相关论文
共 22 条
[1]  
[Anonymous], 2000, AM J RESP CRIT CARE, V161, pS221
[2]   Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists [J].
Carmona, L ;
Gómez-Reino, JJ ;
Rodríguez-Valverde, V ;
Montero, D ;
Pascual-Gómez, E ;
Mola, EM ;
Carreño, L ;
Figueroa, T .
ARTHRITIS AND RHEUMATISM, 2005, 52 (06) :1766-1772
[3]  
Farhat M, 2006, INT J TUBERC LUNG D, V10, P1192
[4]   TUMOR-NECROSIS-FACTOR-ALPHA IS REQUIRED IN THE PROTECTIVE IMMUNE-RESPONSE AGAINST MYCOBACTERIUM-TUBERCULOSIS IN MICE [J].
FLYNN, JL ;
GOLDSTEIN, MM ;
CHAN, J ;
TRIEBOLD, KJ ;
PFEFFER, K ;
LOWENSTEIN, CJ ;
SCHREIBER, R ;
MAK, TW ;
BLOOM, BR .
IMMUNITY, 1995, 2 (06) :561-572
[5]  
Fonseca Joao Eurico, 2006, Acta Reumatol Port, V31, P247
[6]   Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk -: A multicenter active-surveillance report [J].
Gómez-Reino, JJ ;
Carmona, L ;
Valverde, VR ;
Mola, EM ;
Montero, MD .
ARTHRITIS AND RHEUMATISM, 2003, 48 (08) :2122-2127
[7]   Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection [J].
Gomez-Reino, Juan J. ;
Carmona, Loreto ;
Descalzo, Miguel Angel .
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2007, 57 (05) :756-761
[8]   Priorities for the treatment of latent tuberculosis infection in the United States [J].
Horsburgh, CR .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (20) :2060-2067
[9]   Tuberculosis associated with infliximab, a tumor necrosis factor (alpha)-neutralizing agent [J].
Keane, J ;
Gershon, S ;
Wise, RP ;
Mirabile-Levens, E ;
Kasznica, J ;
Schwieterman, WD ;
Siegel, JN ;
Braun, MM .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (15) :1098-1104
[10]   Tuberculosis infection in the United States - National trends over three decades [J].
Khan, Kamran ;
Wang, Jun ;
Hu, Wei ;
Bierman, Arlene ;
Li, Yukit ;
Gardam, Michael .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2008, 177 (04) :455-460